Ginkgo Bioworks Holdings (DNABW) Income from Non-Controlling Interests (2020 - 2022)
Ginkgo Bioworks Holdings (DNABW) reported Income from Non-Controlling Interests of $2.4 million for Q4 2022, up 155.08% on a YoY basis from $936954.3 in Q4 2021, and up 236.96% quarter-over-quarter from -$1.7 million in Q2 2022.
Ginkgo Bioworks Holdings (DNABW) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
Ginkgo Bioworks Holdings has reported Income from Non-Controlling Interests for 3 years, with the latest figure at $2.4 million in Q4 2022.
- For the quarter ending Q4 2022, Income from Non-Controlling Interests rose 155.08% year-over-year to $2.4 million; the trailing twelve-month figure through Sep 2023 stood at $2.4 million (up 129.25% YoY), and the FY2022 full-year result was -$1.4 million, up 78.12% from the prior year.
- Income from Non-Controlling Interests for Q4 2022 stood at $2.4 million, up from -$1.7 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $2.4 million in Q4 2022, with the low at -$4.3 million in Q4 2021.
- Historically, Income from Non-Controlling Interests has averaged -$968888.9 across 3 years, with a median of -$753000.0 in 2020.
- Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests tumbled 838.03% — and 2022, when it surged 155.08%.
- Ginkgo Bioworks Holdings' Income from Non-Controlling Interests stood at -$753000.0 in 2020, then tumbled by 476.23% to -$4.3 million in 2021, then surged by 155.08% to $2.4 million in 2022.
- The last three Income from Non-Controlling Interests figures came in at $2.4 million (Q4 2022), -$1.7 million (Q2 2022), and -$2.1 million (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | - | - | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.39 Mn |
| Jun 30, 2022 | -1.75 Mn |
| Mar 31, 2022 | -2.09 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -524,000.00 |
| Jun 30, 2021 | -523,000.00 |
| Mar 31, 2021 | -1.21 Mn |
| Dec 31, 2020 | -753,000.00 |
| Sep 30, 2020 | 71,000.00 |